Paratek Pharmaceuticals has acknowledged the receipt of a letter from NexPoint Asset Management but disagrees with its characterizations. The company will provide more information on its acquisition by Gurnet Point Capital and Novo Holdings A/S when it files proxy materials with the SEC. This news may not have a significant short-term impact on the stock price, but it shows that Paratek is addressing concerns from its stockholders.